NALBUPHINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nalbuphine Hydrochloride, and when can generic versions of Nalbuphine Hydrochloride launch?
Nalbuphine Hydrochloride is a drug marketed by Abbott, Abbvie, Dr Reddys, Hospira, Igi Labs Inc, and Rising. and is included in fifteen NDAs.
The generic ingredient in NALBUPHINE HYDROCHLORIDE is nalbuphine hydrochloride. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nalbuphine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nalbuphine Hydrochloride
A generic version of NALBUPHINE HYDROCHLORIDE was approved as nalbuphine hydrochloride by HOSPIRA on February 3rd, 1989.
Summary for NALBUPHINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 15 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 22 |
Clinical Trials: | 103 |
Patent Applications: | 660 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NALBUPHINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for NALBUPHINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Assiut University | Early Phase 1 |
Sinew Pharma Inc. | Phase 2 |
Li-Jen Hsin | Phase 4 |
Pharmacology for NALBUPHINE HYDROCHLORIDE
Drug Class | Opioid Agonist/Antagonist |
Mechanism of Action | Competitive Opioid Antagonists Partial Opioid Agonists |